Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of latanoprost in eyes with uveitic glaucoma

  • Glaucoma
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To compare the efficacy and safety of latanoprost against a fixed combination of dorzolamide and timolol in eyes with elevated intraocular pressure (IOP) or glaucoma and anterior or intermediate uveitis.

Methods

Fifty-eight patients with anterior or intermediate uveitis and elevated IOP or glaucoma presented or followed up in the Ocular Inflammation and Immunology Service of General Hospital of Athens were randomly assigned to receive treatment either with latanoprost (30) or with dorzolamide/timolol (28). The main outcome measures were inflammatory relapses and IOP response to treatment.

Results

Ten patients (34%) in the latanoprost group and sixteen patients (57%) in the dorzolamide/timolol group experienced relapses of anterior uveitis (p = 0.93). There was no statistical difference between the two groups in respect of inflammatory relapses (p = 0.21). Twenty-one patients were followed up before starting latanoprost. The number of recurrences of anterior uveitis per patient per year before treatment with latanoprost was 0.82 ± 1.2. The rate of relapses per patient per year after starting latanoprost was 0.39 ±0.7 for these patients (p = 0.038). After 1 year of treatment, intraocular pressure was dropped from 27.8 ± 8.4 mmHg to 18.6 ± 5.3 mmHg (p < 0.001) in the latanoprost group and from 28.2 ±8.1 mmHg to 22.6 ±10.1 mmHg (p < 0.001) in the dorzolamide/timolol group. Four patients during treatment with latanoprost and five patients during treatment with dorzolamide/timolol developed macular edema.

Conclusion

Latanoprost is safe and equally effective to a fixed combination of dorzolamide and timolol in the treatment of uveitic glaucoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kok H, Barton K (2002) Uveitic glaucoma. Ophthalmol Clin North Am 15:375–387, doi:10.1016/S0896-1549(02)00028-7

    Article  PubMed  Google Scholar 

  2. Moorthy RS, Mermoud A, Baerveldt G, Minckler DS, Lee PP, Rao NA (1997) Glaucoma associated with uveitis. Surv Ophthalmol 41:361–394, doi:10.1016/S0039-6257(97)00006-4

    Article  PubMed  CAS  Google Scholar 

  3. Papadaki TG, Zacharopoulos IP, Pasquale LR, Christen WB, Netland PA, Foster CS (2007) Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol 144:62–69, doi:10.1016/j.ajo.2007.03.013

    Article  PubMed  Google Scholar 

  4. Eakins KE (1977) Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res 25:483–498, doi:10.1016/S0014-4835(77)80043-2

    Article  PubMed  CAS  Google Scholar 

  5. Ziai N, Dolan JW, Kacere RD, Brubaker RF (1993) The effects on aqueous dynamics of PhXA41, a new prostaglandin in normal and ocular hypertensive human eyes. Arch Ophthalmol 111:1351–1358

    PubMed  CAS  Google Scholar 

  6. Arcieri ES, Pierre Filho PT, Wakamatsu TH, Costa VP (2008) The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye 22:179–183, doi:10.1038/sj.eye.6702542

    Article  PubMed  CAS  Google Scholar 

  7. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R (1998) Anterior uveitis associated with latanoprost. Am J Ophthalmol 126:37–41, doi:10.1016/S0002-9394(98)00071-3

    Article  PubMed  CAS  Google Scholar 

  8. Warwar RE, Bullock JD, Ballal D (1998) Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 105:263–268, doi:10.1016/S0161-6420(98)92977-3

    Article  PubMed  CAS  Google Scholar 

  9. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC (1999) Latanoprost 0.005% and anterior uveitis. Acta Ophthalmol Scand 77:668–672, doi:10.1034/j.1600-0420.1999.770612.x

    Article  PubMed  CAS  Google Scholar 

  10. Sacca S, Pascotto A, Siniscalchi C (2001) Ocular complications of latanoprost in uveitic glaucoma: three case reports. J Ocul Pharmacol Ther 17:107–113, doi:10.1089/10807680151125393

    Article  PubMed  CAS  Google Scholar 

  11. Sung V, Barton K (2004) Management of inflammatory glaucomas. Curr Opin Ophthalmol 15:136–140, doi:10.1097/00055735-200404000-00014

    Article  PubMed  Google Scholar 

  12. Schumer RA, Camras CB, Mandahl AK (2002) Putative side effects of prostaglandin analogs. Surv Ophthalmol 47(Suppl 1):S219, doi:10.1016/S0039-6257(02)00328-4

    Article  PubMed  Google Scholar 

  13. Alm A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with Timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743–1752

    PubMed  CAS  Google Scholar 

  14. Camras CB (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 103:138–147

    PubMed  CAS  Google Scholar 

  15. Watson P, Stjernschantz J (1996) A six-month, randomized, double-masked studycomparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126–137

    PubMed  CAS  Google Scholar 

  16. Mishima HK, Masuda K, Kitazawa Y (1996) A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 114:929–932

    PubMed  CAS  Google Scholar 

  17. Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47(Suppl 1):S203–S218, doi:10.1016/S0039-6257(02)00294-1

    Article  PubMed  Google Scholar 

  18. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA (2005) Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 21:242–249, doi:10.1089/jop.2005.21.242

    Article  PubMed  CAS  Google Scholar 

  19. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA (2004) COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 82:42–48, doi:10.1046/j.1600-0420.2004.0205.x

    Article  PubMed  CAS  Google Scholar 

  20. Honrubia FM, Larsson LI, Spiegel D (2002) European latanoprost study group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 80:635–641, doi:10.1034/j.1600-0420.2002.800615.x

    Article  PubMed  CAS  Google Scholar 

  21. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 140:509–516, doi:10.1016/j.ajo.2005.01.035

    Article  PubMed  Google Scholar 

  22. Markomichelakis NN, Halkiadakis I, Pantelia E, Georgalas E, Chrysanthi K, Theodossiadis P, Moschos M, Theodossiadis G, Kouvatseas G (2007) Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm 15(2):71–79, doi:10.1080/09273940701244509

    Article  PubMed  Google Scholar 

  23. Chang JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, Lightman S (2008) Use of ocular hypotensive prostaglandin analogues in patients with uveitis: Does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol 92:916–921, doi:10.1136/bjo.2007.131037

    Article  PubMed  CAS  Google Scholar 

  24. Wand M, Gilbert CM, Liesegang TJ (1999) Latanoprost and herpes simplex keratitis. Am J Ophthalmol 127:602–604, doi:10.1016/S0002-9394(99)00050-1

    Article  PubMed  CAS  Google Scholar 

  25. Ekatomatis P (2001) Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol 85:1008–1009, doi:10.1136/bjo.85.8.1007a

    Article  PubMed  CAS  Google Scholar 

  26. Morales J, Shihab ZM, Brown SM, Hodges MR (2001) Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol 132:114–116, doi:10.1016/S0002-9394(01)01012-1

    Article  PubMed  CAS  Google Scholar 

  27. Herpetic Eye Disease Study Group (2000) Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch Ophthalmol 118:1030–1036

    Google Scholar 

  28. Herpetic Eye Disease Study Group (1998) Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 339:300–306, doi:10.1056/NEJM199807303390503

    Article  Google Scholar 

  29. Martin L (1999) Clinical experience with latanoprost: a retrospective study of 153 patients. Acta Ophthalmol Scand 77:336–339, doi:10.1034/j.1600-0420.1999.770318.x

    Article  PubMed  CAS  Google Scholar 

  30. DuBiner HB, Mroz M, Shapiro AM, Dirks MS (2001) Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 23:1969–1983, doi:10.1016/S0149-2918(01)80150-8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ocular Immunology and Inflammation Service, Department of Ophthalmology, General Hospital of Athens, 106 Kykladon Street, Ag. Paraskevi, Athens, 15341, Greece

    Nikos N. Markomichelakis & Agori Kostakou

  2. Ophthalmiatrion Athinon, Athens Eye Hospital, Athens, Greece

    Agori Kostakou, Ioannis Halkiadakis & Sonia Chalkidou

  3. Department of Ophthalmology, Medical School, University of Athens, Athens, Greece

    Dimitrios Papakonstantinou & Gerasimos Georgopoulos

Authors
  1. Nikos N. Markomichelakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agori Kostakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ioannis Halkiadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sonia Chalkidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitrios Papakonstantinou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerasimos Georgopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nikos N. Markomichelakis.

Additional information

The authors have no proprietary interest in any aspect of this study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markomichelakis, N.N., Kostakou, A., Halkiadakis, I. et al. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 247, 775–780 (2009). https://doi.org/10.1007/s00417-009-1036-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-009-1036-3

Keywords

Search

Navigation